Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.59 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794742 | 1.00 | AR (0.59) | ARSLC22A12PGR | |
| Hydrochloric Acid SCHEMBL30636352 | 0.98 | AR (0.58) | ARSLC22A12PGR | |
| Hydrochloric Acid SCHEMBL22117993 | 0.98 | AR (0.58) | ARSLC22A12PGR | |
| Hydrochloric Acid SCHEMBL3872539 | 0.98 | AR (0.58) | ARSLC22A12PGR | |
| Bromide SCHEMBL30389929 | 0.98 | AR (0.58) | ARSLC22A12PGR | |
| Ammonia Solution, Strong SCHEMBL27656720 | 0.98 | AR (0.58) | ARSLC22A12PGR | |
| Hydrogen Sulfide SCHEMBL28182413 | 0.94 | AR (0.54) | ARSLC22A12PGR | |
| SCHEMBL28311735 | 0.92 | AR (0.53) | ARSLC22A12PGR | |
| Isothiocyanate SCHEMBL28855999 | 0.90 | AR (0.51) | ARSLC22A12PGR | |
| SCHEMBL28485189 | 0.88 | SLC22A12 (0.55) | ARSLC22A12PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-3131588-B1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4594324-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2025-08-06 | — | — | EP | claimed |
| EP-4543870-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-04-30 | — | — | EP | claimed |
| CN-119654312-A | Substituted tetrazolyl compounds useful as T cell activators | 百时美施贵宝公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119591582-A | Imide-based proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-119490427-A | Preparation method of 2-trifluoromethyl benzamide | 宁夏忠同生物科技有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-115677522-B | Preparation method of o-trifluoromethyl benzamide and intermediate thereof | 浙江巍华新材料股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3135669-B1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | DONG A ST CO LTD (KR) | 2024-08-28 | — | — | EP | claimed |
| WO-2024068976-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-04 | — | — | WO | claimed |
| CN-1127753-A | New imidazolidines substituted by a heterocycle, their preparation process and intermediates, their use as medicaments NAD the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-07-31 | — | — | CN | claimed |
| EP-0704448-A1 | Heterocyclic substituted imidazolidines, process and intermediates for their preparation, their use as medicaments and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1996-04-03 | — | — | EP | claimed |
| WO-1995018794-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1995-07-13 | — | — | WO | claimed |
| EP-0578516-A1 | Optionally substituted phenylimidazolidins, process for their preparation, their use as medicaments and the pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1994-01-12 | — | — | EP | claimed |
| CN-1063102-A | New phenylimidazolidines,, prepare they method, they are as the application of medicine and the pharmaceutical composition that contains them | ROUSSEL UCLAF (FR) | 1992-07-29 | — | — | CN | claimed |
| US-5126497-A | Catalyst and process for the preparation of trifluoromethyltoluenes | OCCIDENTAL CHEMICAL CORPORATION (US) | 1992-06-30 | — | — | US | claimed |
| US-5084478-A | Antiandrogens for treatment of prostatic disease, acne, hirsutism or seborrhoea | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-28 | — | — | US | claimed |
| US-4808746-A | Preparation of trifluoromethylbenzonitrile from trifluoromethylbenzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 1989-02-28 | — | — | US | claimed |
| EP-0097357-B1 | PROCESS FOR PREPARING TRIFLUOROMETHYLBENZENE DERIVATIVES | Daikin Kogyo Co., Ltd. (JP) | 1986-01-08 | — | — | EP | claimed |
| US-4493800-A | REACTING A TRIFLUOROMETHYLHALOGENOBENZENE WITH COPPER CYANIDE | DAIKIN KOGYO CO., LTD. (JP) | 1985-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN3 | AR 1177/4885SLC22A12 4333/4885PGR 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.